Education
About Us
Working with TipRanks
Follow Us
Nuformix Plc (GB:NFX)
LSE:NFX
NFX Stock Chart & Stats
0.23p
<0.01p(2.11%)
At close: 4:00 PM EST
0.23p
<0.01p(2.11%)
Day’s Range― - ―
52-Week Range0.07p - 0.56p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£5.70M
Enterprise Value4.86M
Total Cash (Recent Filing)£97.55K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,109,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free / Very Low LeverageA debt-free balance sheet materially lowers insolvency risk and gives management optionality to prioritize R&D or licensing discussions without debt covenants. Over 2–6 months this structural flexibility supports strategic partnering and staged financing choices rather than firefighting liquidity.
Clear Niche: Repurposing And Reformulating DrugsA well-defined strategy targeting reformulation and drug-delivery for fibrosis leverages existing safety data and can shorten development timelines versus novel drugs. That business model is attractive to partners and reduces scientific/clinical risk, supporting license or collaboration pathways over coming months.
Reduced Loss In 2025 Vs 2024A materially smaller 2025 loss indicates management has tightened costs or completed one-off recapitalization actions. If sustained, this trend can extend runway, lower near-term funding needs, and improve negotiating leverage with potential partners or investors over the medium term.
Bears Say
No Recent RevenueZero revenue across multiple years means the business lacks proven commercialization and must rely on external funding or partnerships to validate commercial potential. This structural absence of operational income increases execution risk and prolongs dependency on dilutive financing.
Persistent Negative Cash FlowConsistent negative operating and free cash flow implies ongoing cash burn and the need for recurrent financing. Over several months this creates dilution risk, constrains the ability to advance multiple programs simultaneously, and forces prioritization that may delay development milestones.
Eroded Equity And Small Asset BaseA materially shrunken equity and asset base weakens the company's cushion against setbacks and limits internal funding capacity for trials. Structurally, this elevates the probability of dilution or distressed financing if clinical or regulatory timelines slip, increasing operational vulnerability.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07p and its highest was 0.56p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £5.70M.
When is Nuformix Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuformix Plc’s earnings last quarter?
Currently, no data Available
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,109,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―